Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Horner

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Chronic Respiratory Disease|December 4, 2020
Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases-Network-analyses and multivariate modelsDavid Lang, Kaveh Akbari, Stefan Walcherberger, et al.
The European Respiratory Journal|June 8, 2023
The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypesJoan B Soriano, Andreas Horner, Michael Studnicka, et al.
The Journal of Biological Chemistry|May 7, 2013
The bacterial translocon SecYEG opens upon ribosome bindingDenis G Knyazev, Alexander Lents, Eberhard Krause, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 9, 2020
Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA ProjectAndreas Horner, Otto C Burghuber, Sylvia Hartl, et al.
Cancers|December 10, 2021
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict OutcomesDavid Lang, Linda Ritzberger, Vanessa Rambousek, et al.
Cancers|January 11, 2022
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort StudyDavid Lang, Anna Brauner, Florian Huemer, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort studyDavid Lang, Andreas Horner, Elmar Brehm, et al.
Nanoscale Advances|September 22, 2022
Interaction of the motor protein SecA and the bacterial protein translocation channel SecYEG in the absence of ATPKlemens Winkler, Andreas Karner, Andreas Horner, et al.
Biomolecules|February 26, 2025
Enhanced Site-Specific Fluorescent Labeling of Membrane Proteins Using Native NanodiscsBence Ezsias, Felix Wolkenstein, Nikolaus Goessweiner-Mohr, et al.
Lung Cancer (Auckland, N.Z.)|December 30, 2020
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive StudyDavid Lang, Wolfgang Haslinger, Kaveh Akbari, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Chronic Respiratory Disease|December 4, 2020
Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases-Network-analyses and multivariate modelsDavid Lang, Kaveh Akbari, Stefan Walcherberger, et al.
The European Respiratory Journal|June 8, 2023
The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypesJoan B Soriano, Andreas Horner, Michael Studnicka, et al.
The Journal of Biological Chemistry|May 7, 2013
The bacterial translocon SecYEG opens upon ribosome bindingDenis G Knyazev, Alexander Lents, Eberhard Krause, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 9, 2020
Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA ProjectAndreas Horner, Otto C Burghuber, Sylvia Hartl, et al.
Cancers|December 10, 2021
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict OutcomesDavid Lang, Linda Ritzberger, Vanessa Rambousek, et al.
Cancers|January 11, 2022
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort StudyDavid Lang, Anna Brauner, Florian Huemer, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort studyDavid Lang, Andreas Horner, Elmar Brehm, et al.
Nanoscale Advances|September 22, 2022
Interaction of the motor protein SecA and the bacterial protein translocation channel SecYEG in the absence of ATPKlemens Winkler, Andreas Karner, Andreas Horner, et al.
Biomolecules|February 26, 2025
Enhanced Site-Specific Fluorescent Labeling of Membrane Proteins Using Native NanodiscsBence Ezsias, Felix Wolkenstein, Nikolaus Goessweiner-Mohr, et al.
Lung Cancer (Auckland, N.Z.)|December 30, 2020
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive StudyDavid Lang, Wolfgang Haslinger, Kaveh Akbari, et al.
Pageof 7